The scientific and clinical research process is a complicated and time-consuming affair, and with good reason, as human life and safety hang in the balance. To accelerate this critical pathway, a team of scientists, PhD degrees, and drug development experts have built the first technology that improves these processes by an estimated 50x, while also improving success rates.
The clinical trial process came to mainstream attention in 2020 during the development of the COVID-19 vaccines. While that process was significantly accelerated due to urgent public need, there were still some hold-ups, and each day of delay is believed to have cost human lives.
Typically, it takes seven to ten years for a drug to go through the entire clinical trial process, with each drug costing between $1.5 billion and $2.5 billion by the time it reaches patients. Unfortunately, anywhere between 90% and 95% of clinical trials fail, leading to huge amounts of wasted resources and effort.
In order to bring a drug or medical device to market, the developer has to present a large volume of meticulously conducted research to satisfy stringent regulatory requirements and establish that the product is safe and effective. Each phase of the clinical trial is designed to answer a different set of questions, with successive phases addressing a larger pool of patients.
One of the reasons clinical trials can take so long is that there are significant inefficiencies during the research process, where huge volumes of data need to be harmonized from disparate sources. Most of these sources can be accessed only through specialized yet rudimentary search engines that are limited in scope. Regulatory guidelines are also scattered, making it challenging for drug developers to design studies that satisfy multiple stakeholders.
In recent years, advancements in artificial intelligence, particularly generative AI and large language models (LLMs), have helped people analyze vast amounts of data and extract information in a format that is coherent and understandable. However, mainstream AI programs, such as ChatGPT, Bard, and Bing AI, have been found to sometimes “hallucinate,” or produce a response that is not factual, which limits their utility in medical and scientific fields.
The lengthy and complex process of clinical research and drug development presents challenges for researchers and pharmaceutical companies. To address these pain points, Philadelphia-based BioPhy has developed a generative AI solution that streamlines the drug development process by efficiently processing large volumes of data, enabling faster and more informed decision-making, at scale. It helps users quickly gain an understanding of complex biomedical concepts, clinical research, and regulatory logic.
David Latshaw II, Ph.D
BioPhyRx is designed to help researchers quickly synthesize and analyze large volumes of literature, clinical trials data, and regulatory guidelines. The platform is a centralized, intuitive research tool that enables researchers to access the scientific and regulatory resources they need with increased speed and ease, by providing accurate summaries, and comprehensive analysis and interpretation of scientific literature, clinical trials, and regulatory guidelines - while also being trained on regulations from the FDA and EMA. It is currently being used by pharmaceutical and biotechnology companies across the full spectrum of drug development from pre-clinical, through approval, regulatory, manufacturing, R&D, and drug repurposing. Unlike other AI models, BioPhyRx cites outside sources for each response to avoid unsubstantiated "hallucinations." It also stays up-to-date on the latest research and policies, ensuring users receive the most current information and remain compliant throughout the drug development process
By centralizing access to critical resources and automating laborious tasks, the team of AI and Drug Development experts at BioPhy aspire to bring new levels of predictability and risk quantification to the historically risky process of drug development. If successful, BioPhyRx could help reduce the high failure rates of clinical trials and enable researchers to more efficiently develop safer, more effective medicines.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. and Nasdaq® is a registered trademark of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as , either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. © 2023. Nasdaq, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.